πŸ‡ΊπŸ‡Έ FDA
Patent

US 10612027

Modified double-stranded RNA agents

granted A61PA61P43/00

Quick answer

US patent 10612027 (Modified double-stranded RNA agents) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61P, A61P43/00